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Background: Dysfunctional high-density lipoprotein (HDL) may have pro-inflammatory effects on the endothelial
cells,which causes atherosclerosis in type 2 diabetes mellitus (T2DM). HDL is a major carrier of
sphingosine-1-phosphate (S1P) in plasma while S1P exhibits multiple biological activities. However, potential role of
HDL and S1P in T2DM remains unexplored. We hypothesized that diabetic HDL with higher contents of S1P exerts
beneficial effects on the vascular system.
Methods: Subjects with T2DM with or without proved large arteries atherosclerosis and normal controls (n=15 for
each group) were recruited in the present study. HDL was isolated from the subjects by ultracentrifugation. The
levels of HDL-associated S1P were determined by UPLC-MS/MS. The protective function of diabetic HDL and S1P
was evaluated by measuring cyclooxygenase-2 (COX-2) expression and prostacyclin I-2 (PGI-2) release by human
umbilical vein endothelial cells (HUVECs) using western blot and enzyme-linked immunosorbent assay (ELISA),
respectively.
Results: The S1P levels in isolated HDL were significantly increased in T2DM subjects compared with controls
(235.6 ± 13.4 vs 195.0 ± 6.4 ng/mg, P< 0.05). The diabetic HDL exerted greater protective effects on inducing COX-2
expression and PGI-2 release by HUVECs than those of control HDL (p < 0.05, p < 0.01, respectively). Pertussis toxin,
a common inhibitor of G-couple protein receptors, and VPC 23019, an antagonist of S1P receptor 1 and 3
significantly attenuated HDL-induced COX-2 expression and PGI-2 release.
Conclusions: Diabetic HDL carries higher level of S1P compared with normal HDL, which has the potential to
contribute to protective effects on endothelial cells by inducing COX-2 expression and PGI-2 release. These findings
provide a new insight of S1P function in T2DM patients, possibly leading to a new therapeutic target.
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The rising incidence and complications of type 2 diabetes
mellitus (T2DM) are becoming major public health
problems [1]. One of the most serious complications of
T2DM is atherosclerosis, a vascular disease, which
accounts for 80% of diabetic mortality. Due to the close
links between atherosclerosis, T2DM and cardiovascular
diseases, endothelial self-protection and dysfunction are
more considered in therapeutic strategies of T2DM [2].
High-density lipoprotein (HDL) conveys an impressive
spectrum of vascular-protective properties. In addition to
its role in reverse cholesterol transport, HDL also exerts
beneficial effects on anti-oxidative, anti-inflammatory,
anti-thrombotic and endothelium-dependent vaso-re-
laxation [3]. It has been shown that the impaired HDL
and apolipoprotein A-I (apoA-I) function contributes,
at least in part, to the development of T2DM-mediated
atherosclerotic vascular disease[4-6].The growing evidence
indicates that sphingosine-1-phosphate (S1P) and HDL
exhibit their biological activities, either alone or in a
combined version [7-9].
HDL normally services as a plasma carrier of S1P and
provides a platform for S1P activities. S1P is generated
from sphingomyelin, one major lipid in the lipid bilayer
of the cell membrane. It is a lipid component of HDL.
S1P is a mediator of many of the cardiovascular protective
effects of HDL, including the ability to inhibit/reverse
atherosclerosis [9,10]. Atherosclerosis is a multi-factorial
inflammatory disease in which cyclooxygenase (COX) and
the downstream diverse prostanoids may play important
role in the development of the disease [11]. It is now known
that the two genes encored two similar but distinct
isoforms of the enzyme, COX-1 and COX-2 [12]. COX-1 is
a non-reducible form of COX protein while the expression
of COX-2 can be regulated [13]. S1P associates with HDL
exerting synergic function in induction of the COX-2
expression and prostaglandin I-2 release [10,14,15].
Although previous studies have shown that in patients
with T2DM the protective functions of HDLs are
impaired [16], it still remains uncertain if these phenomena
differ from various stages of the disease, particularly in the
beginning of it. We hypothesized that the HDL with
increased content of S1P plays a compensatory-protection
role in vascular system in T2DM.
Materials and methods
Subjects
The study was approved by the Institutional Review
Board and the Ethic Committee of Peking University
First Hospital, Beijing, China, and subjects provided
written, informed consent. The inclusion criteria of T2DM
group were 40–75 years old subjects with T2DM diagnoses
in accordance with international standards, fasting plasma
glucose (FPG) ≥ 7.0 mmol/L and glycated hemoglobin(HbA1c) > 6.5%, and T2MD was first diagnosed without
any treatment before. Exclusion criteria of T2DM group
were a history of macrovascular (cardiovascular and
cerebrovascular events) and microvascular disease
(nephropathy absence of albuminuria, retinopathy and
peripheral neuropathy), usage of insulin and statin treat-
ment before. The inclusion criteria of T2DM accompanied
with atherosclerosis (T2DM-As) group were 40–75 years
old subjects with T2DM diagnosed in accordance with
international standards, fasting plasma glucose (FPG) ≥
7.0 mmol/L and glycated hemoglobin (HbA1c) > 6.5%
and confirmed history of macrovascular atherosclerosis
(cardiovascular and cerebrovascular) verified by ultrasound,
computerized tomography angiography (CTA) or magnetic
resonance angiography (MRA).
Cell culture and western blotting
Human umbilical vein endothelial cells (HUVECs) were
isolated from freshly obtained human umbilical cords by
collagenase digestion of the interior of the umbilical vein as
described previously [17]. Cells were used for experiments
prior to their forth passage. Briefly, cells were cultured in
gelatin-coated polystyrene dishes and propagated in endo-
thelial cell medium (ECM) (ScienCell, CA) supplemented
with 5% FBS and endothelial cell growth supplement
(ECGs) (ScienCell, CA) at 37°C in a 5% CO2-humidified
atmosphere. Western blotting was performed as previously
described [18]. After incubation with or without stimuli,
the cultured HUVECs were washed with ice PBS for three
times and then lysed in radioimmuno precipitation assay
buffer. The protein concentration was measured with
bicinchoninic acid (BCA) method according to the instruc-
tions of the company (BCA kit, Pierce, Rockford, IL). An
equal amount of the total protein was subjected to electro-
phoresis and then transferred to nitrocellulose membranes,
incubated in blocking buffer (1% bovine serum albumin in
Tris-buffered saline with 0.1% Tween-20) for 2 hours. The
COX-2 protein was detected by incubating with antibody
against human COX-2 (Cayman Chemical, USA) for eight
hours. After washing, the membrane was incubated in
blocking buffer for 90 min at room temperature and
probed with either HRP-goat-anti-rabbit IgG or HRP-goat-
anti-mouse IgG (MBL, Japan) secondary antibodies
subsequently developed with Western blotting detection
regents by ECL (Piece Biotechnology, IL) according to the
manufacture’s instruction. The densities of specific immu-
noreactive protein bands were quantified using Quantity
One 1-D Analysis Software (Bio-rad, Hercules, CA).
Isolation of HDL
Fasting venous blood samples were drawn on EDTA
tubes from subjects after a 12 h fasting food. Plasma was
immediately collected after centrifugation at 4°C 3,000 rpm
for 10 min. HDL were then isolated from fresh EDTA
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tion (d=1.13–1.21 g∕ mL) as previously described [19].
The isolated HDL was further purified in dialysis of PBS,
sterilized through a 0.22 um filter and stored at 4°C for
the further usage within a month of isolation. The purity
of the HDL was confirmed by SDS-PAGE and western
blot using goat anti-apoA-I polyclonal antibody (DiaSorin,
Stillwater, OK), then quantified through the measurement
of apoA-I content by nephelometry (Dimension XPand,
Dade Behring, Germany). HDL2 (1.063<d<1.125 g/ml)
and HDL3 (1.125<d<1.21 g/ml) were isolated by sequential
ultracentrifugation as previously described [20]. HDL
subfractions were dialyzed against saline/EDTA (150 mM
NaCl, 300 μM EDTA, pH 7.4), sterilized by filtering
through a 0.22 μm membrane, and stored at 4°C until
used. Equal concentration of apoA-1 in isolated HDL was
used for cell treatment and S1P level determination.
Detection of levels of HDL-associated S1P
UPLC-MS/MS technique was employed to measure
levels of HDL-associated S1P as previously described
[21]. Briefly, after loading of HDL samples (200 μL for
each test) to a 1.5 ml centrifuge tube, methanol (800 μL)
and methanol with standard C17-D-erythro-sphingosine-1-
phosphate (C17-sph) (50 μl of 1000 μg/L) were added to
the same tube and then shaken vigorously for 1 minute.
After centrifugation at 12,000 rpm for 15 minutes, the
supernatant was collected and analysis of S1P was per-
formed by a Waters ACQUITY UPLCTM system. Waters
ACUITY UPLC BEH Phenyl column (1.8 μm; 2.1 mm ×
100 mm) was selected for chromatographic separation. The
injection volume was 5 μL. Methanol (A) and 0.5% formic
acid in ultrapure water (B) were used as mobile phases. The
gradient started at 10% A and then increased linearly to
60% in 6 minutes, to 100% at 6 minutes and kept for
2 minutes, followed by a decrease to initial conditions of
10% A and held for 2 minutes to allow for equilibration.
The flow rate was 0.3 mL/min. The column was maintained
at 40°C, and the sample room temperature was 10°C.
S1P was analyzed by MS/MS in the multiple-reaction
monitoring (MRM) mode. The optimized MS/MS
parameters for the analyses including their precursor
and product ions, cone voltage, and collision energy












S1P 0.1 380 25 265 18
82 40
C17-sph 0.1 366 25 251 18
82 40Eight points calibration curves for S1P were constructed
for the standard solutions between 7.8 and 1000 μg/L,
and calibration graphs were linear with good correlation
coefficients (r2>0.99). Recoveries of target compounds
were 89±4% in isolated HDL by spiking standards of S1P
(500 ng/mL) to HDL samples (n=3). The limits of detection
(LODs) were estimated to be 30 ng/mL for HDL based on
the peak-to-peak noise of the baseline and on a minimal
value of signal-to-noise of 3 and LOD, respectively.
Concentrations of S1P in plasma or HDL samples were
corrected by C17-sph.
ELISA for quantitation of 6-keto PGF1α production
HUVECs were cultured with or without various HDL
or other reagents for 6 hours. After washing with phos-
phate buffered saline (PBS) at 37°C, cells were incubated
with 1 mL of arachidonic acid (10 μmol/L in 0.75% fatty
acid-free BSA/PBS buffer) at 37°C for further 30 minutes.
Supernatants were collected for measurement of produc-
tion of 6-keto PGF1α, an inactive, non-enzymatic hydrolysis
product of PGI-2. Concentrations of 6-keto PGF1α in the
supernatants were determined using a 6-keto PGF1α EIA
kit according to the manufacturer’s instructions (Cayman
Chemical, USA). Limit of detection was 6 pg/mL.
S1P associated with BSA and N-HDL
Fatty acid-free BSA and N-HDL were used as a carrier
for exogenous S1P. S1P (2 nM) was added into tubes
containing 30 μg/ml of BSA or N-HDL separately overnight
at 4°C for further usage.
Statistical analysis
The results are presented as the means ± SEM. Data was
analyzed using Mann–Whitney U test and Student’s t test.
For all tests, p < 0.05 was considered significant.
Result
Study participant characteristics
In total 3 groups (15 healthy controls: 9 female, age 60.53 +
14.46 yrs; 15 patients with T2DM: 8 female, age 56.60 +
14.98 yrs; 15 patients with T2DM-As: 8 female, age
57.40±14.67) participated in the study (Table 2). The
subjects with T2DM and with T2DM-As had higher levels
of fasting blood sugar, glycated hemoglobin (HbA1C),
cholesterol, low density lipoprotein-cholesterol (LDL-c),
triglycerides and lower levels of HDL-c than that of the
controls (Table 2). T2DM-As group had higher levels of
fasting blood sugar, glycated hemoglobin (HbA1C),
cholesterol, low density lipoprotein-cholesterol (LDL-c)
and triglycerides than that of the T2DM group.
Increased level of S1P in diabetic HDL
The peak of S1P standard was detected by the methods
described in Method. The HDL-associated S1P was








Age, years 60.53±14.46 56.60±14.98 57.40±14.67
Sex, male/female 6:9 7:8 7:8
Fasting glucose (mmol/L) 5.29±0.35 7.47±2.05* 8.47±1.05*#
HbA1c (%) 5.05±0.35 7.39±0.75* 7.73±0.65*#
Triglycerides (mmol/L) 1.04±0.20 2.13±1.00* 2.72±0.59*#
Total cholesterol (mmol/L) 3.22±0.40 4.70±0.72* 5.31±0.33*#
HDL-c (mmol/L) 1.33±0.11 0.95±0.26* 0.93±0.17*
LDL-c (mmol/L) 1.96±0.23 2.93±0.79* 3.25±0.68*#
Abbreviations: HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density
lipoprotein cholesterol. Values are described as means ± SD.
*P<0.001 versus healthy controls.
# P<0.001 versus T2DM.
Figure 1 Concentrations of HDL-associated S1P in diabetes and
controls. Peaks of S1P standard (A) and S1P in HDL (B) were
obtained by UPLC-MS/MS. The S1P in HDL was extracted following
the method of methanol precipitation of protein. S1P in isolated
HDL-c (C) were compared among controls, type 2 diabetes mellitus
(T2DM) and type 2 diabetes mellitus accompanied with
atherosclersosis (T2DM-As) (n=15 for each group). Mann–Whitney U
test. Bars show medians. * p < 0.05.
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of protein, and the S1P level was detected. The figure
showed the peak of S1P in standard and isolated HDL
(Figure 1A and B). The levels of HDL-associated S1P
were significantly increased in T2DM group compared
with control group (Figure 1C, T2DM vs controls: 235.6 ±
13.4 vs 195.0 ± 6.4 ng/mg, p< 0.05). The levels of HDL-
associated S1P were decreased in T2DM-As group com-
pared with T2DM group (Figure 1C, T2DM-As vs T2DM:
212.5±8.8 vs 235.6 ± 13.4 ng/mg, p< 0.05). There was no
statistical difference between T2DM-As and controls.
Diabetic HDL enhances COX-2 protein expression and
induces PGI-2 release
Using Western blotting technique, we found that cultured
HUVECs spontaneously expressed COX-2 protein at the
baseline. This expression was enhanced by HDL of normal
controls (N-HDL) and diabetic HDL (D-HDL). Equal
concentration of N-HDL and D-HDL (30 μg/mL) was
incubated with endothelial cells for 6 hours. It was great
interesting of that diabetic HDL significantly up-regulated
COX-2 expression by HUVECs than that of HDL from
normal controls (Figure 2A and B). Competitive ELISA
showed that both sources of HDL significantly induced
PGI-2 release (Figure 2C). Again, the effect of diabetic HDL
was greater than that of N-HDL (Figure 2C, D-HDL vs.
N-HDL: 1351 ± 200.1 vs. 666.0±220.8/mL, p<0.001).
Furthermore, both HDL-induced COX-expression and
PGI2 release were concentration-dependent, particularly
in HDL from T2DM (Figure 2D, E and F).
Pertussis toxin attenuates HDL-induced COX-2 expression
and PGI-2 release
To investigate whether the contents of S1P carried per
HDL particle account for the effects of HDL on the
COX-2 expression and PGI-2 release by human vascular
endothelial cells, we used pertussis toxin (PTX), a common
Figure 2 Diabetic HDL induces HUVEC COX-2 expression and PGI-2 release. Cells were incubated with N-HDL (HDL isolated from normal
controls, 30 μg/mL, n=15), D-HDL (HDL isolated from diabetes, 30 μg/mL, n=15) for 6 hours. Cells were cultured with PBS as a negative control.
The expression of COX-2 was assayed by Western blot analysis (A and B). PGI-2 release was determined by competitive ELISA (C). D-F showing
that the effects of HDL on HUVECs were in a concentration-dependent pattern. Data are expressed as the means ± SEM of three independent
experiments. Student’s t test. * p < 0.05. *** p < 0.001.
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the blockage. HUVECs were pre-treated with PTX
(2 ng/mL) for 24 hours and then incubated with or
without HDL isolated from patients with T2DM and
control subjects for further 6 hours. The result showed that
PTX markedly attenuated HDL-induced COX-2 expression
(Figure 3A and B), while the inhibitor also reduced
HDL-induced PGI-2 release (Figure 3C, N-HDL+PTX
vs. N-HDL, 564.0 ± 43.2 vs. 1047 ± 90.9 pg/mL, p<0.001;
D-HDL+PTX vs. D-HDL, 483.8 ± 14.7 vs. 1705 ±
12.3 pg/mL, p<0.001).
VPC 23109,a special antagonist of S1P receptor (1 and 3)
attenuates HDL-induced COX-2 expression and PGI-2
release
S1P induced COX-2 expression by HUVECs, either
alone or associated with HDL (Additional file 1: Figure S1).
To further investigate the effects of S1P on the HDL-
induced responses by human vascular endothelial cells, we
used VPC23019 (Avanti Polar Lipids, Alabaster AL), a
selective antagonist of S1P receptor 1 (S1PR1) and receptor
3 (S1PR3), which have been shown to be involved in the
S1P-mediated processes in HUVECs [22]. HUVECs werepre-treated with VPC23019 (2 nmol) for 20 minutes,then
incubated with or without HDL isolated from patients with
T2DM and control subjects for further 6 hours. The results
showed that VPC23109 diminished the effect of diabetic
HDL on COX-2 expression (Figure 4A and B) and PGI-2
release (Figure 4C, N-HDL vs. PBS control, 1096 ± 114.8
vs. 317.6 ± 28.4 pg/mL, p <0.001; D-HDL vs. N-HDL,
1745 ± 50.9 vs. 1096 ± 114.8 pg/mL, p<0.001; N-HDL+VPC
vs. N-HDL, 587.1 ± 84.6 vs. 1096 ± 114.8 pg/mL, p<0.001;
D-HDL+VPC vs. D-HDL, 440.4 ± 32.0 vs. 1745 ±
50.9 pg/mL, p<0.001).
Discussion
Previous studies of diabetic HDL have been focusing on
its pro-inflammatory role and dysfunctions such as
reverse cholesterol transport (3). In diabetes mellitus,
disorders of carbohydrate, fat and protein metabolism
result in modifications of HDL protein and lipid compo-
nents, which may lead to functional deficiency of plasma
HDL [23]. Consistent high levels of blood glucose may not
only cause protein glycosylation, resulting in dysfunction of
reverse cholesterol transport and anti-inflammatory effects,
but may also cause disorder in lipid metabolism which
Figure 3 Pertussis toxin (PTX) attenuates HDL-induced HUVEC
COX-2 expression and PGI-2 release. Cells were preincubated
with PTX (2 ng/ml) for 24 hours. Cells were further incubated with
30 μg/ml of N-HDL or D-HDL for 6 hours. The expression of COX-2
was measured by Western blotting (A, B) and the PGI-2 release was
determined by the competitive ELISA (C). In all experiments above,
PBS was used as vehicle control. Data are expressed as the means ±
SEM of three independent experiments. Student’s t test. ** p < 0.01,
*** p < 0.001.
Figure 4 VPC 23109 attenuates HDL-induced HUVEC COX-2
expression and PGI-2 release. VPC 23019 attenuated HDL-induced
COX-2 expression (A, B) and PGI-2 release (C) by HUVECs. In these
experiments, cells were pre-treated VPC 23019 (2 nmol/ml) for
20 minutes and then incubated with 30 μg/ml of N-HDL or D-HDL
for further 6 hours. The measurements of COX-2 expression (A, B)
and PGI-2 release (C) were same as above. In all experiments above,
PBS was used as vehicle control. Data are expressed as the means ±
SEM of three independent experiments. Student’s t test. * p < 0.05.
** p < 0.01, *** p < 0.001.
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These modifications greatly affect clearance of HDL and
apoA-I from circulation [24,25]. On the other hand, the
increased non-enzymatic glycosylation of the major apoli-
poprotein, including apoA-I secondary to hyperglycemia
impairs cholesterol transport and its anti-inflammatory
function [26,27]. In fact, all changes should gradually occur
because T2DM is a chronic disease. Therefore, the body of
patient tries to compensate the dysfunctional changes at
the beginning of abnormal metabolism while disease itself
may be a result of decompensation of the body. During the
compensated stage, patients usually exhibit few symptoms
of diabetes without complications of vascular damagedue to the body’s compensatory protective regulations.
However, there is insufficient evidence showing whether
there are some compensatory protective effects, including
the effects of HDL in patients with T2DM. The relationship
between the changes of level of HDL-associated S1P and
the disease progression, like atherosclerosis, is still unclear
due to the lack of longitudinal studies.
In this study, we have generated a body of data
supporting the hypothesis that HDL and S1P play some
compensatory protective effects in the diabetic status.
Subjects of T2DM had higher levels of triglycerides, total
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compared with that of controls. On the other hand, the
levels of HDL-associated S1P suggesting that S1P may
be one of compensatory mechanisms in the early stage
of T2DM. This increased content of S1P associated with
HDL is possibly due to alternated capacity of HDL loading
more S1P from plasma, or increased concentration of
plasma S1P, or both [28]. Also, the levels of S1P associated
with HDL from T2DM-As were decreased than early
T2DM, suggesting that diabetic HDL may lose its
compensatory effects as disease progresses. The levels
of S1P associated with diabetic HDL3 were higher
than that of native HDL3 implying that this difference
of S1P might be because of the alteration of S1P in
HDL3. It is now known that diabetes causes alteration
in the sphingolipids metabolism [29]. However, these
studies have focused on sphingosine, but not S1P, a
downstream product of the metabolism. S1P is generated
from the phosphorylation of sphingosine catalyzed by two
sphingosine kinase isoenzymes, SphK1 and SphK2 [30].
Slight changes in the levels of sphingomyelin, ceramide or
sphingosine are able to significantly increase the level of
S1P. Studies of S1P biological functions suggest that S1P
may play different roles in various conditions. For
instance, the increased S1P levels have been observed in
the animal models of type 1 diabetes, type 2 ob/ob mice
and diabetic humans and implicated in pro-thrombotic
and pro-inflammatory effects [24,31]. S1P accounts for
several antiatherogenic and anti-inflammatory effects of
HDL. S1P also antagonizes endothelial dysfunction by
preventing monocyte/endothelial interactions through
activation S1PR1 in the type 1 NOD mouse model and has
vascular protective properties, whereas S1PR1 activation
promotes eNOS activation and nitric oxide production
[32]. Our data also showed that HDL with higher content
of S1P upregulated COX-2 expression and PGI-2 release
by human vascular endothelial cells, two important athero-
protective factors [33].
S1P receptors belong to G-coupled receptors while
human vascular endothelial mainly express two of S1P
receptors, S1PR1 and S1PR3. To investigate whether the
effects of HDL on HUVEC were mediated through S1P,
we employed a common G-PRC inhibitor pertussis toxin
and S1PR1 and 3 specific antagonist VPC 23019. It has
been shown in a previous study in which the expression
of S1PR1 was higher in diabetes than controls, suggesting
that S1P and its receptors might play important role in dia-
betes [34]. Our data showed that up to 80% HDL-mediated
effects on COX-2 expression and PGI-2 release was
blockaded by these two inhibitors, suggesting that the
effects of HDL on HUVEC largely contribute the contents
of S1P in HDL. G-PCR is large group of receptors which
located on cell membrane. We used PTX as a general
blocker of G-PCR. On the other hand, we used VPC23109,a selective blocker of S1PR1 and 3, to narrow down the
range of these blockages inhibiting the specific effects of
S1P and its receptors. Selective blockage of S1PR1 and 3
seemed weaker than that of general G-PCR inhibitor PTX,
particularly in COX-2 expression. A potential explanation
is that other G-PCRs except for S1PR1 and 3 may also have
similar effects. Previous studies have shown that S1P was
associated with apolipoprotein M (apoM) in HDL exerted
its biological function [35]. But the effects of S1P associated
with apoM in metabolic disease are still unknown. Whether
any changes of modification and function of apoM in
T2DM needs further investigations.
Normally, with developing of disease, the metabolic
process starts dynamically from balance to unbalance,
from compensation to decompensation. Similar status
may occur in S1P in HDL, while HDL might finally lose
the compensatory effects. Some clinical trials have
shown that “glycemic lowering therapies” and “intensive
lipid lowering treatment” might not decrease mortality
caused by macrovascular events in T2DM [36]. There-
fore, it is necessary to further understand the potential
mechanism of the lipid metabolism in HDL in T2DM,
particularly in the early stage of the disease.
We also evaluated other effects of diabetic HDL,
especially leucocyte-endothelial interaction. Compared
with N-HDL, diabetic HDL enhanced more THP-1 cells
to adhere to HUVECs, which is possibly associated with
increased expression of adhesion molecules, including
ICAM-1 and VCAM-1 (Additional file 1: Figure S2).
Previous studies have shown that advanced glycation end
products (AGEs) play an important role in impairing
endothelial progenitor cell (EPC) functions, which may
contribute to the development of vascular diseases in
diabetes [37].
In conclusion, our data suggests that diabetic HDL
with higher content S1P may exert some protective
effects on vascular endothelial system, as a kind of the
body’s compensatory mechanism preventing or delaying
complications from the disease. Future studies should
extend its other protective effects and focus on therapeutic
potential in this area.Additional file
Additional file 1: Figure S1. S1P associated with BSA and N-HDL
enhanced COX-2 expression by HUVECs,which was attenuated by S1PR1
and S1PR3 antagonist, VPC 23019. A and B: HUVECs were pre-treated
with antagonist VPC 23019 (2 nmol/ml) for 20 minutes and then
incubated with 0.5% BSA, S1P (2 μM of S1P carried by 0.5% BSA), N-HDL
(30 μg/ml) and S1P-N-HDL (2 μM of S1P carried by 30 μg/ml of N-HDL)
for 6 h to measure the expression of COX-2 by Western blotting. S1P-BSA
and S1P-N-HDL significantly increased the expression of COX-2 compared
with BSA and N-HDL alone. Figure S2: Diabetic HDL enhanced adhesion
molecule expression compared with N-HDL. A and B: HUVECs were
incubated with PBS, N-HDL or D-HDL (1 mg/ml) for 6 hours. THP-1
monocytic cells were then overlaid on the cells. Fifteen minutes later,
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photographs showing adhered THP-1 cells at various conditions. B: the
numbers of adhered THP-1 cells to pre-treated HUVECs. The results are
the means ± SEM of three wells from three independent experiments. C
and D: HUVECs were similarly incubated for 6 h with the indicated
concentrations of N-HDL or D-HDL for the measurement of ICAM-1 (C)
and VCAM-1 (D) protein expression. The results are presented as the
mean of SEM of OD volume of three individual experiments.
Abbreviations
T2DM: Type2 diabetes mellitus; HDL: High-density lipoprotein;
S1P: Sphingosine-1-phosphate; COX-2: Cyclooxygenase-2; PGI-2: Prostacyclin
I-2; HUVECs: Human umbilical vein endothelial cells; S1PR1: S1P receptor 1;
S1PR3: S1P receptor 3.
Competing interest
The authors declare they have no competing interests.
Authors’ contribution
As to the contribution of each author, Xunliang Tong, Lemin Zheng and
Yining Huang designed the study, analyzed and interpreted the results, and
drafted the manuscript; Hui Peng and Jianying Hu were involved in the
UPLC-MS/MS performance; Donghui Liu, Liang Ji and Chenguang Niu made
substantial contributions to performing the experimental protocol; Jun Ren
and Bing Pan were involved in revising the manuscript critically for
important intellectual content. All authors participated in the discussion and
interpretation of the results and in the final approval of the manuscript
submitted.
Acknowledgements
This project was supported by Grants 2008ZX09312-017 from National S&T
Major Project of China, 2010CB912504 and 2011CB503900 from “973”
National S&T Major Project, 30900595, 81170101, and 30821001 from the
National Natural Science Foundation of China, 7102104 and 7122106 from
the Natural Science Foundation of Beijing, China.
Dr. Yining Huang and Dr. Lemin Zheng are the guarantors of this work, had
full access to all the data, and take full responsibility for the integrity of data
and the accuracy of data analysis. No other potential conflicts of interest
relevant to this article were reported.
Author details
1Department of Neurology, Peking University First Hospital, Beijing 100034,
China. 2The Institute of Cardiovascular Sciences and Institute of Systems
Biomedicine, School of Basic Medical Sciences, and Key Laboratory of
Molecular Cardiovascular Sciences, Ministry of Education, Key Laboratory of
Cardiovascular Molecular Biology and Regulatory Peptides, Ministry of Health,
Peking University Health Science Center, Beijing 100191, China. 3College of
Urban and Environmental Sciences, Peking University, Beijing 100871, China.
4Division of Kinesiology and Health & Biomedical Science PhD Program,
University of Wyoming College of Health Sciences, Laramie, WY, USA.
Received: 23 November 2012 Accepted: 28 January 2013
Published: 30 January 2013
References
1. Neeli H, Gadi R, Rader DJ: Managing diabetic dyslipidemia: beyond statin
therapy. Curr Diab Rep 2009, 9(1):11–17.
2. Plutzky J, Viberti G, Haffner S: Atherosclerosis in type 2 diabetes mellitus
and insulin resistance: mechanistic links and therapeutic targets.
J Diabetes Complications 2002, 16(6):401–415.
3. Sorci-Thomas MG, Thomas MJ: High density lipoprotein biogenesis,
cholesterol efflux, and immune cell function. Arterioscler Thromb Vasc Biol
2012, 32(11):2561–2565.
4. Patel S, Drew BG, Nakhla S, Duffy SJ, Murphy AJ, Barter PJ, Rye KA, Chin-Dusting J,
Hoang A, Sviridov D, et al: Reconstituted high-density lipoprotein increases
plasma high-density lipoprotein anti-inflammatory properties and cholesterol
efflux capacity in patients with type 2 diabetes. J Am Coll Cardiol 2009,
53(11):962–971.
5. Calkin AC, Drew BG, Ono A, Duffy SJ, Gordon MV, Schoenwaelder SM, Sviridov
D, Cooper ME, Kingwell BA, Jackson SP: Reconstituted high-densitylipoprotein attenuates platelet function in individuals with type 2 diabetes
mellitus by promoting cholesterol efflux. Circulation 2009, 120(21):2095–2104.
6. Drexel H, Aczel S, Marte T, Vonbank A, Saely CH: Factors predicting
cardiovascular events in statin-treated diabetic and non-diabetic patients
with coronary atherosclerosis. Atherosclerosis 2010, 208(2):484–489.
7. Sato K, Okajima F: Role of sphingosine 1-phosphate in anti-atherogenic
actions of high-density lipoprotein. World J Biol Chem 2010, 1(11):327–337.
8. Lucke S, Levkau B: Endothelial functions of sphingosine-1-phosphate.
Cell Physiol Biochem 2010, 26(1):87–96.
9. Argraves KM, Gazzolo PJ, Groh EM, Wilkerson BA, Matsuura BS, Twal WO,
Hammad SM, Argraves WS: High density lipoprotein-associated
sphingosine 1-phosphate promotes endothelial barrier function.
J Biol Chem 2008, 283(36):25074–25081.
10. Argraves KM, Argraves WS: HDL serves as a S1P signaling platform mediating a
multitude of cardiovascular effects. J Lipid Res 2007, 48(11):2325–2333.
11. Liu D, Ji L, Wang Y, Zheng L: Cyclooxygenase-2 Expression, Prostacyclin
Production and Endothelial Protection of High-density Lipoprotein.
Cardiovasc Hematol Disord Drug Targets 2012, 12:98.
12. Martinez-Gonzalez J, Badimon L: Mechanisms underlying the cardiovascular
effects of COX-inhibition: benefits and risks. Curr Pharm Des 2007,
13(22):2215–2227.
13. Kimura T, Sato K, Malchinkhuu E, Tomura H, Tamama K, Kuwabara A,
Murakami M, Okajima F: High-density lipoprotein stimulates endothelial
cell migration and survival through sphingosine 1-phosphate and its
receptors. Arterioscler Thromb Vasc Biol 2003, 23(7):1283–1288.
14. Sattler K, Levkau B: Sphingosine-1-phosphate as a mediator of high-density
lipoprotein effects in cardiovascular protection. Cardiovasc Res 2009,
82(2):201–211.
15. Rodriguez C, Gonzalez-Diez M, Badimon L, Martinez-Gonzalez J:
Sphingosine-1-phosphate: A bioactive lipid that confers high-density
lipoprotein with vasculoprotection mediated by nitric oxide and
prostacyclin. Thromb Haemost 2009, 101(4):665–673.
16. Eren E, Yilmaz N, Aydin O: High Density Lipoprotein and it's Dysfunction.
Open Biochem J 2012, 6:78–93.
17. Jaffe EA, Nachman RL, Becker CG, Minick CR: Culture of human endothelial
cells derived from umbilical veins. Identification by morphologic and
immunologic criteria. J Clin Invest 1973, 52(11):2745–2756.
18. Burnette WN: "Western blotting": electrophoretic transfer of proteins
from sodium dodecyl sulfate–polyacrylamide gels to unmodified
nitrocellulose and radiographic detection with antibody and
radioiodinated protein A. Anal Biochem 1981, 112(2):195–203.
19. Chung BH, Wilkinson T, Geer JC, Segrest JP: Preparative and quantitative
isolation of plasma lipoproteins: rapid, single discontinuous density gradient
ultracentrifugation in a vertical rotor. J Lipid Res 1980, 21(3):284–291.
20. Lee MH, Hammad SM, Semler AJ, Luttrell LM, Lopes-Virella MF, Klein RL:
HDL3, but not HDL2, stimulates plasminogen activator inhibitor-1
release from adipocytes: the role of sphingosine-1-phosphate. J Lipid Res
2010, 51(9):2619–2628.
21. Kingsley PJ, Marnett LJ: Analysis of endocannabinoids, their congeners
and COX-2 metabolites. J Chromatogr B Analyt Technol Biomed Life Sci
2009, 877(26):2746–2754.
22. Saba JD, Hla T: Point-counterpoint of sphingosine 1-phosphate
metabolism. Circ Res 2004, 94(6):724–734.
23. Onat A, Hergenc G: Low-grade inflammation, and dysfunction of
high-density lipoprotein and its apolipoproteins as a major driver of
cardiometabolic risk. Metabolism 2011, 60(4):499–512.
24. Fox TE, Bewley MC, Unrath KA, Pedersen MM, Anderson RE, Jung DY,
Jefferson LS, Kim JK, Bronson SK, Flanagan JM, et al: Circulating sphingolipid
biomarkers in models of type 1 diabetes. J Lipid Res 2011, 52(3):509–517.
25. Mooradian AD: Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract
Endocrinol Metab 2009, 5(3):150–159.
26. Fleisher LN, Tall AR, Witte LD, Miller RW, Cannon PJ: Stimulation of arterial
endothelial cell prostacyclin synthesis by high density lipoproteins. J Biol
Chem 1982, 257(12):6653–6655.
27. Liu D, Ji L, Zhang D, Tong X, Pan B, Liu P, Zhang Y, Huang Y, Su J, Willard
B, et al: Nonenzymatic glycation of high-density lipoprotein impairs
its anti-inflammatory effects in innate immunity. Diabetes Metab Res
Rev 2012, 28(2):186–195.
28. Hammad SM, Al GM, Semler AJ, Klein RL: Sphingosine 1-phosphate
distribution in human plasma: associations with lipid profiles. J Lipids
2012, 2012:180705.
Tong et al. Cardiovascular Diabetology 2013, 12:27 Page 9 of 9
http://www.cardiab.com/content/12/1/2729. Baranowski M, Blachnio-Zabielska A, Hirnle T, Harasiuk D, Matlak K, Knapp M,
Zabielski P, Gorski J: Myocardium of type 2 diabetic and obese patients is
characterized by alterations in sphingolipid metabolic enzymes but not
by accumulation of ceramide. J Lipid Res 2010, 51(1):74–80.
30. Hannun YA, Obeid LM: Principles of bioactive lipid signalling: lessons
from sphingolipids. Nat Rev Mol Cell Biol 2008, 9(2):139–150.
31. Yeboah J, McNamara C, Jiang XC, Tabas I, Herrington DM, Burke GL, Shea S:
Association of plasma sphingomyelin levels and incident coronary heart
disease events in an adult population: Multi-Ethnic Study of
Atherosclerosis. Arterioscler Thromb Vasc Biol 2010, 30(3):628–633.
32. Whetzel AM, Bolick DT, Srinivasan S, Macdonald TL, Morris MA, Ley K,
Hedrick CC: Sphingosine-1 phosphate prevents monocyte/endothelial
interactions in type 1 diabetic NOD mice through activation of the S1P1
receptor. Circ Res 2006, 99(7):731–739.
33. Arehart E, Gleim S, Kasza Z, Fetalvero KM, Martin KA, Hwa J: Prostacyclin,
atherothrombosis, and cardiovascular disease. Curr Med Chem 2007,
14(20):2161–2169.
34. Duru EA, Fu Y, Davies MG: Role of S-1-P receptors and human vascular
smooth muscle cell migration in diabetes and metabolic syndrome.
J Surg Res 2012, 177(2):e75–e82.
35. Christoffersen C, Obinata H, Kumaraswamy SB, Galvani S, Ahnstrom J,
Sevvana M, Egerer-Sieber C, Muller YA, Hla T, Nielsen LB, et al: Endothelium-
protective sphingosine-1-phosphate provided by HDL-associated
apolipoprotein M. Proc Natl Acad Sci U S A 2011, 108(23):9613–9618.
36. Koshizaka M, Green JB, Alexander JH: Glycemic management in diabetes
and the associated cardiovascular risk: are we helping or hurting our
patients? Circ J 2012, 76(7):1572–1580.
37. Li H, Zhang X, Guan X, Cui X, Wang Y, Chu H, Cheng M: Advanced glycation
end products impair the migration, adhesion and secretion potentials of
late endothelial progenitor cells. Cardiovasc Diabetol 2012, 11:46.
doi:10.1186/1475-2840-12-27
Cite this article as: Tong et al.: High-density lipoprotein of patients with
Type 2 Diabetes Mellitus upregulates cyclooxgenase-2 expression and
prostacyclin I-2 release in endothelial cells: relationship with HDL-
associated sphingosine-1-phosphate. Cardiovascular Diabetology 2013
12:27.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
